- Home
- ATRC vs BCSF Comparison
ATRC vs BCSF Comparison
Compare ATRC & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- BCSF
- Stock Information
- Founded
- ATRC 2000
- BCSF 2015
- Country
- ATRC United States
- BCSF United States
- Employees
- ATRC N/A
- BCSF N/A
- Industry
- ATRC Medical/Dental Instruments
- BCSF Finance/Investors Services
- Sector
- ATRC Health Care
- BCSF Finance
- Exchange
- ATRC Nasdaq
- BCSF Nasdaq
- Market Cap
- ATRC 1.1B
- BCSF 1.1B
- IPO Year
- ATRC 2005
- BCSF 2018
- Fundamental
- Price
- ATRC $31.41
- BCSF $16.94
- Analyst Decision
- ATRC Strong Buy
- BCSF Hold
- Analyst Count
- ATRC 9
- BCSF 4
- Target Price
- ATRC $41.78
- BCSF $16.75
- AVG Volume (30 Days)
- ATRC 438.0K
- BCSF 204.9K
- Earning Date
- ATRC 02-13-2025
- BCSF 02-25-2025
- Dividend Yield
- ATRC N/A
- BCSF 10.64%
- EPS Growth
- ATRC N/A
- BCSF N/A
- EPS
- ATRC N/A
- BCSF 1.99
- Revenue
- ATRC $447,573,000.00
- BCSF $294,257,000.00
- Revenue This Year
- ATRC $17.75
- BCSF N/A
- Revenue Next Year
- ATRC $13.44
- BCSF N/A
- P/E Ratio
- ATRC N/A
- BCSF $8.51
- Revenue Growth
- ATRC 17.56
- BCSF 3.17
- 52 Week Low
- ATRC $18.94
- BCSF $14.78
- 52 Week High
- ATRC $39.05
- BCSF $17.97
- Technical
- Relative Strength Index (RSI)
- ATRC 45.68
- BCSF 43.25
- Support Level
- ATRC $32.03
- BCSF $17.38
- Resistance Level
- ATRC $34.11
- BCSF $17.80
- Average True Range (ATR)
- ATRC 1.33
- BCSF 0.29
- MACD
- ATRC 0.28
- BCSF -0.07
- Stochastic Oscillator
- ATRC 37.76
- BCSF 17.24
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.